A One-Stop-Shop For Biologics Production In Europe
By Louis Garguilo, Chief Editor, Outsourced Pharma

A history of bio-pharma outsourcing is writ large upon the chronicles of Cobra Biologics.
It is the story of three European manufacturing facilities—a former AstraZeneca plant; one built by a Swedish pharmacy in the early sixties; and a biotech’s IC-funded dream—converging over decades and serving as a barometer of industry trends. The story touches topics of past and present, including the:
- vicissitudes of big pharma
- emergence of biotechs and biologics
- cycles of venture capital and economies
- growing centricity of outsourcing service providers
We start with the AstraZeneca facility, in Södertälje, Sweden, 30 kilometers southwest of Stockholm, birthplace of Astra AB. “It was and is today a modern, well equipped facility with two cGMP suites fantastically laid out, and scientists with vast experience producing mammalian and microbial products,” says Peter Coleman, CEO of Cobra Biologics, our bellwether CDMO.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.